Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome.
Adult
Body Composition
/ drug effects
Diet Therapy
Female
Folic Acid
/ administration & dosage
Humans
Inositol
/ administration & dosage
Inositol Phosphates
/ administration & dosage
Menstruation
/ drug effects
Obesity
/ complications
Overweight
/ complications
Polycystic Ovary Syndrome
/ etiology
Polysaccharides
/ administration & dosage
Treatment Outcome
Waist Circumference
/ drug effects
Waist-Hip Ratio
Young Adult
Journal
European review for medical and pharmacological sciences
ISSN: 2284-0729
Titre abrégé: Eur Rev Med Pharmacol Sci
Pays: Italy
ID NLM: 9717360
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
entrez:
28
3
2019
pubmed:
28
3
2019
medline:
14
8
2020
Statut:
ppublish
Résumé
To evaluate, in overweight/obese PCOS women, which of three distinct treatment modalities achieved the greatest clinical benefits in terms of clinical and body composition outcomes. Forty-three polycystic ovary syndrome (PCOS) overweight/obese patients were randomly treated for 6 months with: only diet (Group 1, n = 21); diet and myo-inositol (MI) 4 g + folic acid 400 µg daily (group 2, n = 10); diet in association with MI 1.1 g + D-chiroinositol (DCI) 27.6 mg + folic acid 400 µg daily (group 3, n = 13). Menstrual cycle, Ferriman-Gallwey score, body mass index (BMI), waist circumference, hip circumference, waist-hip ratio (WHR), and body composition by bioimpedentiometry were measured at baseline, 3 and 6 months. Body weight, BMI, waist and hip circumferences decreased significantly in all groups. There was a significant difference between the 3 groups regarding the restoration of menstrual regularity (p = 0.02) that was obtained in all patients only in-group 3. MI+DCI in association with diet seems to accelerate the weight loss and the fat mass reduction with a slight increase of percent lean mass, and this treatment contributes significantly in restoring the regularity of the menstrual cycle.
Identifiants
pubmed: 30915778
doi: 10.26355/eurrev_201903_17278
pii:
doi:
Substances chimiques
Inositol Phosphates
0
Polysaccharides
0
inositol phosphate glycan
0
Inositol
4L6452S749
Folic Acid
935E97BOY8
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM